![Timothy Langer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Timothy Langer
Finanzdirektor/CFO bei Myst Therapeutics LLC
Vermögen: 2 Mio $ am 31.05.2024
Profil
Timothy J.
Langer is associated with Myst Therapeutics LLC as the Chief Financial Officer.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
13.05.2024 | 777 657 ( 3,36% ) | 2 Mio $ | 31.05.2024 |
Aktive Positionen von Timothy Langer
Unternehmen | Position | Beginn |
---|---|---|
Myst Therapeutics LLC
![]() Myst Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Myst Therapeutics LLC is a privately held, pre-clinical stage biotechnology company based in Glendale, CA. Myst Therapeutics LLC focuses on the development and commercialization of novel cancer immunotherapy products that utilize a patient's own immune system to treat solid tumors. Myst is dedicated to improving adoptive cell therapies, particularly neoantigen enriched T cell therapies for solid tumors. By combining methods of identifying neoantigen reactive T cells with their proprietary technologies and expertise in cell therapy development and manufacturing, Myst aims to rapidly advance and commercialize innovative therapies for a wide range of advanced solid tumors. The CEO of the company is Sammy J. Farah. Myst Therapeutics was acquired by Turnstone Biologics, Inc. on January 20, 2021. | Finanzdirektor/CFO | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Myst Therapeutics LLC
![]() Myst Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Myst Therapeutics LLC is a privately held, pre-clinical stage biotechnology company based in Glendale, CA. Myst Therapeutics LLC focuses on the development and commercialization of novel cancer immunotherapy products that utilize a patient's own immune system to treat solid tumors. Myst is dedicated to improving adoptive cell therapies, particularly neoantigen enriched T cell therapies for solid tumors. By combining methods of identifying neoantigen reactive T cells with their proprietary technologies and expertise in cell therapy development and manufacturing, Myst aims to rapidly advance and commercialize innovative therapies for a wide range of advanced solid tumors. The CEO of the company is Sammy J. Farah. Myst Therapeutics was acquired by Turnstone Biologics, Inc. on January 20, 2021. | Commercial Services |